EFFICACY AND SAFETY - OVERVIEW

Not an actual patient.

DUPIXENT is supported by a robust clinical development program

Take a closer look at the efficacy and safety data for DUPIXENT

DUPIXENT was studied in over 2700 patients across 5 pivotal trials for uncontrolled moderate-to-severe atopic dermatitis1

Children
6-11 years of age,
DUPIXENT + TCS
Number
of Patients
367
Pivotal
Trials
1 Concomitant TCS
(Trial 8: 16 weeks)

ADOLESCENTS
12-17 years of age,
DUPIXENT Monotherapy
Number
of Patients
251
Pivotal
Trials
1 Monotherapy
(Trial 6: 16 weeks)

Adults
18+ years of age,
DUPIXENT Monotherapy and + TCS
Number
of Patients
>2100
Pivotal
Trials
2 Monotherapy
(Trials 1 and 2: 16 weeks)
1 Concomitant TCS
(Trial 3: 52 weeks)

Study designs

A robust clinical development program in uncontrolled moderate-to-severe atopic dermatitis

Peak Pruritus
NRS efficacy results

Significant itch relief

IGA efficacy results

Clear or almost-clear skin

EASI efficacy results

Improvement in lesion extent and severity

Real-world results

Clinical trial outcomes supported by real-world data1-3

Adult safety profile

Demonstrated safety across 52 weeks in adults1

The Week 52 safety profile of DUPIXENT + TCS in adults was generally consistent with Week 16 in adults. The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye.1

Adolescent safety profile

Long-term safety observed in adolescents

The long-term safety of DUPIXENT in adolescents was assessed in an open-label extension trial (Trial 7) through Week 521

  • The safety profile at Week 52 was similar to the safety profile observed at Week 16 in Trial 6 (adolescent trial) and in all 3 adult trials
  • The safety profile through Week 16 and Week 52 in adolescents was consistent with that seen in adults

Safety profile in children

Long-term safety observed in children

The long-term safety of DUPIXENT + TCS in children was assessed in an open-label extension study (Trial 7) through Week 521

  • The safety profile in subjects followed through Week 52 was similar to the safety profile observed through Week 16 in Trial 8 (trial in children)
  • The long-term safety profile of DUPIXENT + TCS in children was consistent with that seen in adults and adolescents with atopic dermatitis

References:

  1. DUPIXENT Prescribing Information.
  2. Guttman-Yassky E, Lio PA, Mallya UG, et al. Real-world effectiveness of dupilumab in atopic dermatitis: improvement in itch as assessed by the peak pruritus numerical rating scale (PNRS) in an electronic medical records dataset. Paper presented at: 24th World Congress of Dermatology (WCD); June 10-15, 2019; Milan, Italy.
  3. Eichenfield LF, Gadkari A, Armstrong AW, et al. Real-world effectiveness of dupilumab based on Investigator Global Assessment (IGA) scores and Peak Pruritus Numerical Rating Scale (PNRS) in an electronic medical records dataset. Poster presented at: 77th Annual Meeting of the Society for Investigative Dermatology (SID); May 8-11, 2019; Chicago, IL.

Important Safety
Information and Indication

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Atopic Dermatitis Patients with Comorbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. Healthcare providers and patients may call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/ to enroll in or obtain information about the registry. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information.

Indication

DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.